ARCTURUS THERAPEUTICS HOLDINGS INC. Form 8-K (Oct. 14, 2020)

Summary

Current report on Form 8-K of Arcturus Therapeutics Holdings Inc., date of report October 14, 2020, filed under Item 8.01, Other Events. It states that on October 14, 2020 the company received a non-refundable First Reserve Payment of $12.5 million USD from the Israeli Ministry of Health, associated with a specified clinical trial milestone and provided after a data review of material preclinical and clinical data for the ARCT-021 vaccine candidate. The report says the payment is an initial reserve payment for a specified number of doses under the Supply Agreement executed August 17, 2020, and that the Ministry has become bound to purchase the reserved doses, subject to the agreement's terms. The signature block shows /s/ Joseph E. Payne, Chief Executive Officer.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

Washington,
D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event
reported): October 14, 2020

ARCTURUS THERAPEUTICS HOLDINGS INC.

(Exact name of registrant as specified
in its charter)

Delaware | 001-38942 | 32-0595345
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.)

10628 Science Center Drive , Suite 250

San Diego , California 92121

(Address of principal executive offices)

Registrant’s telephone number,
including area code: (858) 900-2660

(Former name or former address, if changed
since last report)

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common stock, par value $0.001 per share | ARCT | The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events .

On October 14, 2020, Arcturus Therapeutics Holdings Inc., or
the Company, received a non-refundable First Reserve Payment of $12.5 million USD from the Israeli Ministry of Health, or MOH.
This First Reserve Payment of $12.5 million USD is associated with a specified clinical trial milestone, and was provided after
a data review process during which the MOH had access to material preclinical and clinical data for the Company’s COVID-19
vaccine candidate, ARCT-021. This payment serves as an initial reserve payment for a specified number of doses of ARCT-021 pursuant
to a Supply Agreement executed by the Company and the MOH on August 17, 2020. As a result of the making of this payment, the MOH
has become bound to purchase the reserved vaccine doses, as defined in and subject to the terms and conditions of the Supply Agreement.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. | Description of Exhibit
104 | Cover Page to this Current Report on Form 8-K in Inline
XBRL

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Arcturus Therapeutics Holdings Inc.
Date: October 14, 2020
By: | /s/ Joseph E. Payne
Name: | Joseph E. Payne
Title: | Chief Executive Officer

File and source

File

SEC_ARCT_8-K_filed2020-10-15_0001193805-20-001274.htm

Size

22,081 bytes

SHA-256

7746ab35efe76493bc22210b667c50ef135d16de42f74cbe04a0b4d925a81249

Our copy

SEC_ARCT_8-K_filed2020-10-15_0001193805-20-001274.htm

Original

www.sec.gov